Korro Bio, Inc. (KRRO)
Nasdaq: KRRO · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2017
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
| Report filed | Mar 12, 2026 | Mar 18, 2025 | Mar 26, 2024 | Mar 10, 2023 | Mar 15, 2022 | Mar 29, 2021 | Mar 26, 2020 | · | · |
| Revenue | 6,392 | 2,271 | 0 | 0 | 14,068 | 36,984 | 28,947 | · | · |
| For lenders | |||||||||
| Net interest income | · | · | 0 | -118 | · | · | 1,784 | -106 | -174 |
| Research and development | 65,575 | 63,636 | 57,250 | 42,201r | 60,923 | 37,415 | 18,784 | 11,880 | 11,966 |
| General and administrative | 28,159 | 30,545 | 27,284 | 16,797r | 37,176 | 27,119 | 14,838 | 7,064 | 4,340 |
| Total operating expenses | 128,247 | 94,181 | 84,534 | 58,998r | 98,099 | 64,534 | 49,622 | 18,944 | 16,306 |
| Operating income | -121,855 | -91,910 | -84,534 | -58,998r | -84,031 | -27,550 | -20,675 | -18,944 | -16,306 |
| Interest expense | · | · | · | 961 | 764 | 0 | · | · | · |
| Interest and investment income | · | · | · | 1,327 | 397 | 994 | 1,784 | · | · |
| Share of profit of equity-method investments | · | · | · | · | -84,671 | -26,476 | · | · | · |
| Other income (expense), net | 5,232 | 8,470 | 3,389 | 976r | -266 | · | · | · | · |
| Income before income taxes | -116,623 | -83,440 | -81,145 | -58,022r | -84,671 | -26,476 | -18,746 | · | · |
| Income tax expense | 637 | 141 | 27 | 10r | 15 | 35 | 0 | · | · |
| Net income including non-controlling interests | -117,260 | -83,581 | -81,172 | -58,032r | -84,686 | -26,511 | -18,746 | -19,168 | -20,237 |
| Net income | -117,260 | -83,581 | -81,172 | -58,032r | -84,686 | -26,511 | -18,746 | -19,168 | -20,237 |
| Net income to common shareholders | · | · | · | · | -84,686 | -26,511 | -19,800 | -19,168 | -20,237 |
| Earnings per share, basic | -12.48 | -9.37 | -53.08 | -227.42 | · | · | · | · | · |
| Earnings per share, diluted | -12.48 | -9.37 | -53.08 | -227.42 | · | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -2.47 | -0.82 | -2.29 | -12.53 | -28.79 |
| Weighted average shares, basic | 9,395,402 | 8,920,561 | 1,529,321 | 255,175 | · | · | · | · | · |
| Weighted average shares, diluted | 9,395,402 | 8,920,561 | 1,529,321 | 255,175 | · | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 34,351,274 | 32,253,227 | 8,649,245 | 1,530,218 | 702,918 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:Revenues
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxNet interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestShare of profit of equity-method investments its share of companies it partly owns
us-gaap:IncomeLossFromEquityMethodInvestmentsOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted